[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"inadequate-milk-production\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:inadequate-milk-production":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":27,"conditions":28,"keywords":31,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":5},"100409686","phase-2-milk-volume-outcomes-following-oral-nicotinamide-riboside-supplementation-in-mothers-of-extremely-preterm-infants-100409686",false,"NCT04614714","Milk Volume Outcomes Following Oral Nicotinamide Riboside Supplementation in Mothers of Extremely Preterm Infants","Nicotinamide Riboside and Milk Production in the NICU","MOONRISE","Inclusion criteria are required to be met before or at enrollment:\n\nMothers who are 18 years or older.\n\nInfants delivered at 24-32 weeks OR infants (any GA) that researchers anticipate will be hospitalized in the NICU for at least 4 weeks, including, but not limited to, infants with a diagnosis of gastroschisis, a cardiac defect, intestinal atresia, etc.\n\nInfants born at the UC Davis Medical Center or transferred to the UC Davis Medical Center NICU within the first 7 days of life.\n\nMothers who attempted initial milk expression within 12 hours of delivery.\n\nMothers who attempted milk expression at least 6 times every 24 hours from 72 hours after delivery to the Enrollment Visit.\n\nMothers who have delivered at least 96 hours (4 days) prior to the Enrollment Visit.\n\nMothers who have experienced a level \"3\" on the OMPQ before starting the collection of their first 24-hour pooled milk sample (study days 0-3).\n\nMothers who plan to feed their infants breast milk for at least 3 months.\n\nMothers who were pregnant with one infant.\n\nMothers willing to refrain from tandem feeding (directly breastfeeding) another child during the study period.\n\nMothers willing to refrain from enrolling themselves in another intervention trial during the study period.\n\nMothers willing to express, weigh, record, and collect 24-hour pooled milk\n\nMothers willing to remove nipple piercings during the study period.\n\nMothers willing to refrain from using pseudoephedrine (often found in Sudafed, Theraflu, Claritin-D, etc.) during the study period.\n\nMothers willing to express milk 6 times or more every 24 hours, including at least once during the night, and with no more than 5 hours between milk expression sessions, during the study period.\n\nMothers willing to refrain from consuming non-study supplements that contain nicotinamide-riboside (or similar derivatives, including NMN) during the study period.\n\nMothers willing to refrain from consuming galactagogues during the study period.",true,"FEMALE","18 Years",{"count":21,"type":22},40,"ESTIMATED","INTERVENTIONAL",[25,26],"PHASE2","PHASE3","This study aims to evaluate the feasibility and effects of nicotinamide riboside (NR) supplementation in lactating mothers of infants expected to be hospitalized in the neonatal intensive care unit (NICU) for at least four weeks.",[29,30],"Preterm Birth","Inadequate Milk Production",[32,33,34,35,36],"Nicotinamide Riboside","milk volume","Neonatal intensive care unit","Galactagogue","Feasibility trial","NOT_YET_RECRUITING","2026-05-14",{"date":40,"type":41},"2026-05-18","ACTUAL",{"date":43,"type":22},"2026-06-01",{"date":45,"type":22},"2026-06-30",{"name":47,"class":48},"University of California, Davis","OTHER"]